Safety and efficacy of a 6-month home-based exercise program in patients with facioscapulohumeral muscular dystrophy by Bankolé, Landry-Cyrille et al.
Citation:  Bankolé,  Landry-Cyrille,  Millet,  Guillaume,  Temesi,  John,  Bachasson,  Damien, 
Ravelojaona,  Marion,  Wuyam,  Bernard,  Verges,  Samuel,  Ponsot,  Elodie,  Antoine,  Jean-
Christophe,  Kadi,  Fawzi  and Féasson,  Léonard (2016) Safety and efficacy of  a 6-month 
home-based  exercise  program in  patients  with  facioscapulohumeral  muscular  dystrophy. 
Medicine, 95 (31). e4497. ISSN 0025-7974 
Published by: Lippincott Williams and Wilkins
URL:  http://dx.doi.org/10.1097/MD.0000000000004497 
<http://dx.doi.org/10.1097/MD.0000000000004497>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/35706/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to 
access the University’s research output. Copyright ©  and moral rights for items on NRL are 
retained by the individual author(s) and/or other copyright owners.  Single copies of full items 
can be reproduced,  displayed or  performed,  and given to third parties in  any format  or 
medium for personal research or study, educational, or not-for-profit purposes without prior 
permission or charge, provided the authors, title and full bibliographic details are given, as 
well  as a hyperlink and/or URL to the original metadata page.  The content must  not  be 
changed in any way. Full  items must not be sold commercially in any format or medium 
without  formal  permission  of  the  copyright  holder.   The  full  policy  is  available  online: 
http://nrl.northumbria.ac.uk/policies.html
This document may differ from the final, published version of the research and has been 
made available online in accordance with publisher policies. To read and/or cite from the 
published version of the research, please visit the publisher’s website (a subscription may be 
required.)
Clinical Trial/Experimental Study Medicine®
OPENSafety and efﬁcacy of a 6-month home-based
exercise program in patients with
facioscapulohumeral muscular dystrophy
A randomized controlled trial
Landry-Cyrille Bankolé, PhDa,b,c,g, Guillaume Y. Millet, PhDa,d,e, John Temesi, PhDa,d,
Damien Bachasson, PhDe,f, Marion Ravelojaona, PhDa,b,g, Bernard Wuyam, MD PhDe,f,g,
Samuel Verges, PhDe,f, Elodie Ponsot, PhDc, Jean-Christophe Antoine, MD PhDg,
Fawzi Kadi, PhDc, Léonard Féasson, MD PhDa,b,g,
∗
Abstract
Background: Previous randomized controlled trials investigating exercise training programs in facioscapulohumeral muscular
dystrophy (FSHD) patients are scarce and of short duration only. This study assessed the safety and efﬁcacy of a 6-month home-
based exercise training program on ﬁtness, muscle, and motor function in FSHD patients.
Methods: Sixteen FSHD patients were randomly assigned to training (TG) and control (CG) groups (both n=8) in a home-based
exercise intervention. Training consisted of cycling 3 times weekly for 35minutes (combination of strength, high-intensity interval, and
low-intensity aerobic) at home for 24 weeks. Patients in CG also performed an identical training program (CTG) after 24 weeks. The
primary outcome was change in peak oxygen uptake (VO2 peak) measured every 6 weeks. The principal secondary outcomes were
maximal quadriceps strength (MVC) and local quadriceps endurance every 12 weeks. Other outcome measures included maximal
aerobic power (MAP) and experienced fatigue every 6 weeks, 6-minute walking distance every 12 weeks, andmuscle characteristics
from vastus lateralis biopsies taken pre- and postintervention.
Results: The compliance rate was 91% in TG. Signiﬁcant improvements with training were observed in the VO2 peak (+19%, P=
0.002) and MAP by week 6 and further to week 24. Muscle endurance, MVC, and 6-minute walking distance increased and
experienced fatigue decreased. Muscle ﬁber cross-sectional area and citrate synthase activity increased by 34% (P=0.008) and
46% (P=0.003), respectively. Dystrophic pathophysiologic patterns were not exacerbated. Similar improvements were experienced
by TG and CTG.
Conclusions:A combined strength and interval cycling exercise-training program compatible with patients’ daily professional and
social activities leads to signiﬁcant functional beneﬁts without compromising muscle tissue.
Abbreviations: ANOVA = analysis of variance, CG = control group, CTG = control-training group, FSHD = facioscapulohumeral
muscular dystrophy, MAP = maximal aerobic power, MVC = maximal voluntary contraction, T = time (in weeks from baseline
measures, T0), TG = training group, VO2 peak = peak oxygen uptake.
Keywords: combined strength and endurance training, exercise training, facioscapulohumeral muscular dystrophy, home-based,
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Facioscapulohumeral muscular dystrophy (FSHD) is an incur-
able[1] progressive autosomal-dominant neuromuscular disease
initially affecting face, shoulder girdle, and upper arm muscles.
The muscle weakness that develops is typically asymmetric,
progressively worsening with increasing muscle wasting,[2]
associated with fatigue, reduced endurance, and increased
ventilatory needs during normal daily activities.[3] Reports
indicate peak oxygen uptake (VO2 peak) is lower in patients
with neuromuscular diseases compared to nondiseased sedentary
controls.[4] Muscle weakness and fatigue, mobility impairment,
and reduced physical activity contribute to progressive general
health deterioration including physical, mental, and social
dimensions.[5]
There is a great potential role for exercise in neuromuscular
disease populations, especially dystrophic myopathies,[6,7] for the
prevention of excessive fatigue and to limit muscle atrophy and
cardiorespiratory and metabolic deconditioning. Only 3 aerobic-
training[6,8,9] and 2 strength-training[10,11] studies have been
performed on FSHD patients. Aerobic training increased aerobic
capacity and quality of life.[8,9] Conversely, maximal strength
gains via resistance training remain equivocal. Combined aerobic
and strength training, however, may be more effective than
aerobic training alone[5,7] yet no study has investigated combined
aerobic and strength training in FSHD patients. There is also a
lack of long-term studies on FSHD and exercise, speciﬁcally long-
term exercise effects on muscle and patient autonomy and
whether regular exercise can realistically be integrated into
patients’ daily lives.Figure 1. Global view of the experimental protocol. MAP=maximal aerobic pow
uptake.
2Therefore, a randomized controlled trial was conducted to
investigate the effects of a 24-week adapted home-based exercise
training program designed to be compatible with FSHD patients’
daily professional, social, and familial activities.We hypothesized
that the program, combining high-intensity, low-intensity
aerobic and strength exercises, would improve aerobic capacity,
muscle characteristics (i.e., histological, chemical) and function
(i.e., strength, fatigue, endurance), and quality of life.2. Methods
2.1. Study design
A 24-week multicenter randomized controlled trial with outcome
assessments at 0 (T0), 6 (T6), 12 (T12), 18 (T18), and 24 (T24)
weeks for training (TG) and control (CG) groups was performed
(Fig. 1). A second 24-week nonrandomized trial from T24 to 48
(T48) weeks after the start of the randomized controlled trial was
then performed by CG patients wishing to perform the same
supervised home-based training program (CTG).
2.2. Participants
Nineteen FSHD patients were enrolled (Fig. 2) in this multicenter
study conducted at Centre Hospitalier Universitaire de Saint-
Etienne and Centre Hospitalier Universitaire de Grenoble,
France. Eligible participants were identiﬁed through the
Rhône-Alpes Referent Center for Rare Neuromuscular Diseases,
France. Inclusion criteria were (i) molecular FSHD Type 1
diagnosis, (ii) age ≥ 18 years, and (iii) the ability to perform theer; T= time (in weeks from baseline measures, T0); VO2 peak=peak oxygen
Figure 2. Study ﬂow diagram. CG=control group; CTG=control-training group; TG= training group.
Bankolé et al. Medicine (2016) 95:31 www.md-journal.comcycling program in this study. Exclusion criteria were a history of
cardiovascular disease including cardiac arrhythmias and clinical
cardiovascular anomaly, evidence of inﬂammatory syndrome or
diabetes, abnormal coagulation, or body mass index ≥ 35 kg
m2. All procedures were performed in accordance with the
Declaration of Helsinki and approved by the local ethics3committee (Comité de Protection des Personnes Sud-Est 1,
France). All participants gave written informed consent. This trial
is registered with ClinicalTrials.gov, number NCT01116570.
None of the patients had previously participated in a study
including a physical exercise program. Patients were randomly
allocated to TG (6 men, 4 women) or CG (8 men, 1 woman). The
Bankolé et al. Medicine (2016) 95:31 Medicinestudy administrative coordinator performed a computer-gener-
ated pairwise randomization by enrolment order, ensuring
similar numbers of patients allocated to each group. Patients
were informed of group allocation group when a sealed envelope
was opened in their presence. Due to the nature of the training
study, investigators involved in training and testing patients were
unable to be blinded. All histological analyses were conducted by
individuals blinded to training status.2.3. Procedures
At least 3 weeks before the start of the experimental period,
patients underwent baseline testing (T0) comprising 3 visits
separated by ≥ 72hours at the closest partner laboratory (Saint-
Etienne or Grenoble). Visit 1 consisted of quadriceps neuromus-
cular function (i.e., strength, fatigability, endurance) assessment
(QIF-test)[12,13] and 6-minute walking test. During visit 2,
patients performed an incremental cycling test to task failure and
completed questionnaires about perceived fatigue and quality of
life. The same investigator performed muscle biopsies at both
centers during visit 3 using the Weil–Blakesley percutaneous
conchotome technique.[14] Creatine kinase concentrations were
measured before training at baseline and 24hours after each
functional evaluation session (see Fig. 1). In the nonrandomized
trial, CG values at T24 were considered baseline for CTG. The
randomized controlled trial interassessment period was 6 weeks
and increased to 8 weeks in the nonrandomized trial to facilitate
compliance over the additional 24 weeks.
Aside from the training program, patients in all groups were
instructed not to change normal daily activities or habits.
Training consisted of three 35-minute cycling sessions per week
at home performed entirely on a stationary ergocycle (Fig. 3).Figure 3. Training sessions. Content of (A) the combined aerobic/stren
4Two combined sessions consisted of aerobic exercise at constant
moderate intensity (60% of maximal aerobic power, MAP)
followed by sets of near-maximal revolutions. Session 3 consisted
of interval training (see Fig. 3). The ﬁrst 5 to 10 training sessions
were supervised by an exercise physiologist experienced in
training clinical populations at the patients’ homes. Every week,
the exercise physiologist provided telephone support for 2
sessions and attended the third session to supervise it, assess heart
rate recorded from each training session, verify training log
completion, check equipment, and adjust the individualized
exercise intensity based on either observed heart rate reduction
with training or the new MAP from incremental cycling
assessments.
2.4. Outcomes
Peak oxygen uptake was the primary outcome measure of the
study. Both VO2 peak and MAP were assessed using an
incremental cycling test performed on a stationary bicycle
(Monark Ergomedic, 839E, Vansbro, Sweden) with breath-by-
breath gas analysis and electrocardiogram (Ergocard, Medisoft,
Sorinnes, Belgium). Power output was increased every 2minutes
(10–30W increment) until task failure. VO2 peak was considered
as the oxygen consumption during the last 30 s before task
failure and MAP as the power output of the last completed stage
plus 25% of per stage increment for each additional 30 s
completed. Before and 3minutes after exercise termination, a
20-μL capillary blood sample was collected for lactate concen-
tration determination.[15]
Quadriceps neuromuscular function was assessed by the QIF
test as previously developed and validated in FSHD patients by
our group (typical error coefﬁcient of variation of voluntarygth and (B) interval training sessions. MAP=maximal aerobic power.
Bankolé et al. Medicine (2016) 95:31 www.md-journal.comactivation and evoked force responses< 8 and 10%, respectively;
intraclass correlation coefﬁcient> 0.85).[12] Patientswere seated in
a custom chair with hips at 130° and knees at 90° and
noncompliant straps securing the hips and chest. Force was
measured via force transducer (SBB 200kg Tempo Technologies,
Taipei, Taiwan) connected by noncompliant strap to the ankle,
sampled at 2000Hz and analyzed using Labchart 8 software
(ADInstruments, Bella Vista, Australia). Torque was calculated as
force measured by the force transducer multiplied by the length of
the lever arm. The test consisted of stages of 10 intermittent
submaximal isometric contractions (5-s on/5-s off) with neuro-
muscular evaluations before the QIF-test, immediately after each
stage and immediately after task failure. The neuromuscular
evaluation was composed of isometric maximal voluntary
contractions (MVCs) with femoral nerve magnetic stimuli
delivered duringMVCs and at rest. Magnetic stimulation (FNMS)
was delivered via 2Magstim 200 stimulators (Magstim,Whitland,
UK) connected by Bistim module and a 45-mm ﬁgure-eight coil.
Submaximal target torques started at 10%MVC for the ﬁrst stage
and increased by 10% MVC per stage until task failure. Target
torque levels were identical for a given patient throughout the
intervention (i.e., as a percentage of T0 MVC). Peak MVC and
evoked torques in relaxed muscle and maximal voluntary
activation were also calculated. In addition to pre-post changes
for each test, data from the 10% to 40% MVC stages were
analyzed because they were completed by all patients for all tests.
Participant adherence is reported as the percentage of
scheduled training sessions completed.
Muscle damage 24hours after neuromuscular and physiologi-
cal assessments (incremental cycling, fatigue, and strength tests)
was assessed from serum creatine kinase concentrations. All
patients had serum creatine kinase analysis performed at their
same local laboratory.
The 6-minute walking test to assess motor function consisted of
walking as far as possible in 6minutes and was conducted as
previously described.[16]
Quality of life and perceived fatigue were respectively
evaluated by 2 questionnaires validated in French: the Short
Form Health Survey (SF-36) and Fatigue Severity Scale.
Subjective ratings of daily levels of soreness and tiredness were
also evaluated. Scoring of these questionnaires has been
previously described.[17–19]
Before and 2 to 7 days after the last training session, muscle
biopsies were obtained from the vastus lateralis in TG and CG.Table 1
Baseline characteristics of participants.
Randomized controlled
CG (n=8)
Participant characteristics
Women/men 1/7
Age, y 41 (9)
Height, cm 177 (11)
Body weight, kg 71.6 (10.5)
Resting heart rate, beats min−1 76 (6)
6-min walking test distance, m 571 (97)
Maximal cycling test
MAP, W 129 (42)
VO2 peak, mL min
−1 kg−1 28.8 (7.0)
Maximal heart rate, beats min−1 178 (16)
Data are mean (SD).
CG=control group, CTG=control-training group, MAP=maximal aerobic power, TG= training group, VO
5The post-training biopsy was taken 2cm vertical and lateral to
the pre-training biopsy site. The procedure used for removing[14]
and conserving muscle samples has been extensively used by our
research group.[20] Fiber type composition andmuscle ﬁber cross-
sectional area were analyzed as previously described.[21,22]
Hemalum eosin safran staining enabled evaluation of common
muscle remodeling signs such as necrotic ﬁbers, ﬁbrosis, and
internalized nuclei.[22] Enzyme activities of creatine kinase,
lactate dehydrogenase, and citrate synthase were determined
ﬂuorimetrically from muscle biopsies.[23]2.5. Statistical analysis
Power assessment for the primary outcome (VO2 peak) was based
on results from Olsen et al.[8] To detect a minimum of 20%
difference fromT0 toT24 between groups (CGandTG), assuming
a of 5% and power of 90%, 12 patients were required per group.
Statistical analyses were performed with Statistica (version 8;
StatSoft, Tulsa). Assumptions of normal data distribution and
variance homogeneity were veriﬁed by Shapiro–Wilk and
Levene’s tests, respectively. The assumption of sphericity was
assessed with Mauchly’s test, and in the case of signiﬁcant
violations, the Greenhouse–Geisser correction was applied. Two-
way (Group  Time) repeated-measures ANOVAs were used to
analyze changes between TG andCG at each time point. Post-hoc
analyses were performed by the Bonferroni multiple comparison
procedure. Pearson’s correlation coefﬁcient was used to deter-
mine relationships between selected variables. For CTG, 1-way
repeated-measures ANOVAs were used to assess the intervention
effect. All analyses were performed with 8 patients per group.
Two-sided statistical signiﬁcance was set at P<0.05.3. Results
Between October 2010 and August 2012, 19 FSHD patients were
enrolled in the study (Fig. 2). Ten patients were allocated to TG (6
men) and 9 patients to CG (8 men). Two patients dropped out in
the TG group before starting the training program, one because
of heart failure and the other for personal reasons. Another
patient, included in CG, withdrew for unknown reasons before
starting the training program. In total 16 patients completed the
study, 8 in TG (5 men) and 8 in CG (7 men) (Table 1). Primary
outcome analysis from 16 patients (8 per group) at the scheduled
study end date showed larger than expected improvements in TGtrial Nonrandomized trial
TG (n=8) CTG (n=8)
3/5 1/7
40 (13) 42 (9)
172 (7) 177 (11)
72.5 (12.3) 72.3 (11.2)
82 (11) 78 (6)
508 (129) 569 (103)
125 (79) 126 (36)
27.3 (12.2) 28.7 (7.9)
168 (17) 180 (13)
2 peak=peak oxygen uptake.
Bankolé et al. Medicine (2016) 95:31 Medicinecompared to CG; thus, the study was concluded despite a smaller
than calculated sample size.
Participant characteristics were similar for CG and TG (all P>
0.05, Table 1). Patients in TG and CTG completed 91 [mean
(SD), 66 (7)] and 83% [60 (10)] of 72 prescribed training
sessions, respectively. No training complications were reported.3.1. Oxygen uptake and aerobic power
Peak oxygen uptake and MAP increased from baseline in TG by
T6 (mean difference in change, 20%, P=0.002 and 27%, P=
0.010, respectively, Table 2, Fig. 4A and B) and continued
through T24. Similarly, CTG VO2 peak and MAP were
signiﬁcantly greater at T48 than T24 (by 17%, P=0.001 and
30%, P=0.001, respectively, Fig. 4A and B). No changes in eitherTable 2
Changes in the main cardio-respiratory, quadriceps function, and fat
trial.
Variables
CG (n=8)
mean (SD)
TG (n=8)
mean (SD)
CG %
(95% CI)
VO2 peak, mL min
1 kg1
T0 28.8 (7.0) 27.3 (12.2) -
T6 27.6 (5.7) 31.1 (12.6) –3.0 (–8.5 to 2.5)
T12 29.1 (6.9) 32.6 (12.4) 1.4 (–4.2 to 7.0)
T18 27.8 (7.8) 33.5 (12.7) –3.1 (–12.8 to 6.5)
T24 28.7 (7.9) 33.6 (12.4) –0.4 (–7.7 to 6.9)
MAP (W)
T0 129 (38) 125 (79) -
T6 129 (38) 149 (83) 1.3 (–4.1 to 6.8)
T12 133 (39) 158 (85) 4.7 (–1.2 to 10.6)
T18 126 (36) 164 (88) 0.6 (–9.5 to 10.6)
T24 129 (37) 170 (87) 2.2 (–6.6 to 11.0)
MVC at rest, N m
T0 125 (35) 125 (47) -
T12 125 (39) 125 (44) –0.2 (–6.3 to 5.8)
T24 124 (40) 139 (47) –1.5 (–5.8 to 2.8)
Voluntary activation at rest, %
T0 95.0 (4.0) 95.5 (3.6) -
T12 95.7 (2.1) 94.5 (4.2) 0.8 (–1.6 to 3.2)
T24 95.2 (2.4) 95.2 (1.9) 0.3 (–3.2 to 3.8)
Muscle endurance (number of repetitions)
T0 55 (5) 56 (7) -
T12 56 (7) 61 (9) 1.5 (–4.4 to 7.4)
T24 53 (8) 66 (14) –3.2 (–11.0 to 4.6)
6-min walking test, m
T0 571 (97) 508 (129) -
T12 566 (117) 550 (136) –1.5 (–6.7 to 3.7)
T24 569 (103) 570 (130) –0.5 (–4.3 to 3.3)
Fatigue Severity Scale (score)
T0 35 (9) 44 (8) -
T6 34 (15) 37 (13) –7.4 (–24.3 to 9.5)
T12 32 (10) 36 (15) –9.0 (–22.7 to 4.7)
T18 37 (12) 35 (14) 5.7 (–12.2 to 23.6)
T24 40 (11) 34 (15) 13.5 (2.2 to 24.8)
Short-Form Health Survey (score)
T0 65 (16) 60 (18) -
T6 70 (13) 60 (21) 10.0 (–2.9 to 22.9)
T12 67 (19) 65 (21) 4.3 (–15.7 to 24.4)
T18 65 (20) 64 (20) 1.4 (–18.3 to 21.1)
T24 60 (17) 69 (20) –7.5 (–16.9 to 2.0)
CI= conﬁdence interval, CG= control group, MAP=maximal aerobic power, MVC=maximal voluntary c
∗
TG as reference for mean difference in change.
6VO2 peak or MAP were observed for CG over the 24 weeks.
Maximal lactatemia did not change for any group (data not
shown).
3.2. Quadriceps intermittent fatigue test
At T24, MVC at rest and muscle endurance were signiﬁcantly
greater versus T0 in TG (mean difference in change, 15%, P=
0.014 and 23%, P=0.018, respectively, Table 2, Fig. 5A and B).
In CTG, MVC was unchanged after 24 weeks of training
althoughmuscle endurance increased by 11% (P=0.007, Fig. 5A
and B). No changes in either MVC or muscle endurance were
observed for CG during the 24-week invention. Changes in both
MVC and MAP in TG were correlated with changes in muscle
endurance (r=0.74, P<0.001 and r=0.60, P=0.001, respec-igue and functional parameters during the randomized controlled
Predicted mean differences (95% CI)
TG %
(95% CI)
Mean difference
in change
∗
% (95% CI) P
- - -
16.7 (7.9 to 25.5) 19.7 (9.1 to 30.3) 0.002
24.1 (9.6 to 38.6) 22.7 (6.8 to 38.6) 0.013
27.3 (13.1 to 41.4) 30.4 (12.9 to 47.9) 0.004
29.0 (10.5 to 47.4) 29.4 (9.1 to 49.5) 0.012
- - -
28.9 (11.6 to 46.1) 27.5 (9.1 to 46.0) 0.010
41.7 (14.1 to 69.2) 36.9 (8.2 to 65.6) 0.022
47.3 (13.3 to 81.4) 46.8 (10.5 to 83.0) 0.022
57.9 (16.3 to 99.5) 55.7 (12.3 to 99.1) 0.022
- - -
0.6 (–1.7 to 2.8) 0.8 (–5.8 to 7.4) 0.814
13.6 (3.9 to 23.2) 15.0 (4.3 to 25.9) 0.014
- - -
–1.1 (–3.2 to 1.1) –1.9 (–5.6 to 1.8) 0.275
–0.2 (–2.5 to 2.0) –0.5 (–5.3 to 4.3) 0.808
- - -
10.3 (1.3 to 19.3) 8.8 (–2.1 to 19.8) 0.130
19.4 (4.8 to 34.0) 22.6 (5.7 to 39.6) 0.018
- - -
8.7 (1.8 to 15.6) 10.2 (1.4 to 19.0) 0.037
13.3 (4.6 to 21.9) 13.7 (4.1 to 23.3) 0.013
- - -
–17.8 (–31.6 to –3.9) –10 .4 (–32.6 to 11.9) 0.368
–19.1 (–34.0 to –4.1) –10.1 (–30.8 to 10.6) 0.347
–22.1 (–36.8 to –7.3) –27.8 (–51.5 to –4.1) 0.034
–25.0 (–39.4 to –10.5) –38.5 (–57.2 to –19.8) 0.001
- - -
8.4 (–33.4 to 50.3) –1.5 (–46.2 to 43.2) 0.947
15.4 (–24.3 to 55.1) 11.1 (–34.3 to 56.4) 0.633
12.3 (–22.9 to 47.5) 10.9 (–30.2 to 52.0) 0.605
22.9 (–15.5 to 61.3) 30.4 (–10.0 to 70.7) 0.155
ontraction, SD= standard deviation, TG= training group, VO2 peak=peak oxygen uptake.
Figure 4. Training effects on cycling parameters. Mean changes in (A) peak
oxygen uptake, (B) maximal aerobic power in the training group versus control
group in the randomized controlled trial and in the control-training group in the
nonrandomized trial.
∗
P<0.05,
∗∗∗
P<0.001, for within-group differences in the
randomized controlled trial compared to T0 (2-way repeated measures
ANOVA); ††P<0.01, †††P<0.001, for differences compared to T24 in the
nonrandomized trial (1-way repeated measures ANOVA). CG=control group;
CTG=control-training group; MAP=maximal aerobic power; T= time (in
weeks from baseline measures, T0); TG= training group; VO2 peak=peak
oxygen uptake.
Bankolé et al. Medicine (2016) 95:31 www.md-journal.comtively) and also between changes in MVC and changes in VO2
peak (r=0.38, P=0.048). No training effect was found for
voluntary activation (Table 2) or evoked torque responses during
the QIF-test in any group (data not shown).
3.3. Six-minute walking test
Over 24 weeks, 6-minute walking test distance increased in TG
(mean difference in change at T24, 14%, P=0.013, Table 2,
Fig. 5C). Similar increases were seen in CTG at T48 (13%, P=
0.007) compared to T24 (Fig. 5C). No changes in 6-minute
walking test distance were observed for CG over the 24 weeks. In
TG, signiﬁcant correlations were found between changes in 6-
minute walking test distance and VO2 peak (r=0.62, P=0.001),
MAP (r=0.72, P<0.001), and MVC (r=0.68, P<0.001).73.4. Quality of life
Quality of life scores from the Short Form Health Survey (SF-36)
did not change signiﬁcantly in either group during the
randomized controlled trial (Table 2) or in CTG (data not
shown). Fatigue determined by Fatigue Severity Scale question-
naire (Table 2) decreased signiﬁcantly in TG (mean difference in
change T24, –38%, P=0.001, Fig. 5D) and CTG by 22% (P=
0.001, Fig. 5D) at T48. An inverse relationship was found
between changes in Fatigue Severity Scale and changes in Short
Form Health Survey mental health component (r=–0.44, P=
0.023). Changes in Fatigue Severity Scale were also correlated
with changes in the VO2 peak (r=–0.42, P=0.001), MAP
(r=–0.47, P=0.012), muscle endurance (r=–0.58, P=0.002),
MVC (r=–0.56, P=0.002), and 6-minute walking test distance
(r=–0.55, P=0.003). Subjective daily ratings of soreness and
tiredness were unchanged across groups (data not shown).3.5. Creatine kinase
Serum creatine kinase concentrations 24h after maximal cycling
andQIF tests were<1000 IU·L1 at all time points for all groups.
In 1 patient in TG with baseline values >1000 IU·L1, post-
exercise values were between 1000 and 2000 IU·L1 at all time
points.3.6. Muscle biopsy parameters
Muscle biopsy parameter data are presented in Table 3. Muscle
ﬁber cross-sectional area increased in TG relative to unchanged
cross-sectional area in CG (all P<0.05). Citrate synthase
enzymatic muscular activities also increased from T0 to T24 in
TG (P=0.005) whereas the increase in creatine kinase from T0 to
T24 in TG approached signiﬁcance (P=0.055). No change was
observed on muscle ﬁber type composition (data not shown) or
lactate dehydrogenase enzymatic activity in either CG or TG.4. Discussion
This study is the ﬁrst clinical randomized controlled trial
evaluating the safety and efﬁcacy of combined aerobic, high-
intensity interval and strength training onmotor function, muscle
histological and biochemical characteristics and quality of life
over 24 weeks in FSHD patients. The main ﬁndings are that
combined home-based strength and endurance training (i)
increases VO2 peak, MAP, and citrate synthase enzyme activity,
(ii) increases muscle strength and endurance and muscle ﬁber
cross-sectional area, (iii) improves motor function (walking
speed), and (iv) reduces experienced fatigue. The training
intervention did not alter general quality of life or muscle
integrity (serum creatine kinase concentrations and muscle
morphology). Together, these ﬁndings conﬁrm our hypothesis
that combined training is a well-tolerated, safe, and effective
long-term method to induce functional gains without muscle
damage in FSHD patients.
The present training program was more than twice the length
of most previous FSHD training studies. Despite the longer
duration, training adherence (>80%) was similar to shorter
FSHD[8,9] and neuromuscular disease[24,25] studies. This con-
trasts a recent 16-week training intervention[6] where 39% of
FSHD patients had unacceptable adherence, with travel time to
the study site stated as 1 reason for lower adherence levels. In the
present study, all sessions were closely supervised in person or by
Figure 5. Training effects on neuromuscular, motor, and subjective parameters. Mean changes in (A) isometric maximal voluntary strength, (B) number of
submaximal repetitions (muscle endurance), (C) 6-min walking test distance, and (D) experienced fatigue (Fatigue Severity Scale score) in the training group versus
control group in the randomized controlled trial and in the control-training group in the nonrandomized trial.
∗
P<0.05,
∗∗
P<0.01,
∗∗∗
P<0.001 for within-group
differences in the randomized controlled trial compared to T0 (2-way repeated measures ANOVA); †P<0.05, ††P<0.01, for differences compared to T24 in the
nonrandomized trial (1-way repeated measures ANOVA). CG=control group; CTG=control-training group; MVC=maximal voluntary contraction; T= time (in
weeks from baseline measures, T0); TG= training group.
Bankolé et al. Medicine (2016) 95:31 Medicinetelephone. As training was performed at home, time constraints
imposed by traditional rehabilitation programs at clinical centers
were avoided. This result supports a therapeutic approach for
FSHD patients based on closely supervised home-based training
to promote patient participation.
A major concern was whether FSHD patients could perform
long-term exercise training safely and without muscle damage. In
TG, subjective ratings of perceived soreness and fatigue and
serum creatine kinase concentrations remained unchangedTable 3
Changes in muscle cross-sectional area and enzyme activities in the
Variables
CG (n=8)
mean (SD)
TG (n=8)
mean (SD)
C
(9
Muscle cross-sectional area, mm2
Type I Fibers T0 7453 (1946) 5296 (1153)
T24 7080 (2653) 6818 (2084) –4.0 (–2
Type II Fibers T0 7426 (2162) 5455 (1392)
T24 7145 (2540) 7558 (2220) –4.3 (–1
Whole muscle T0 7060 (1879) 5392 (1165)
T24 7101 (2495) 7214 (2247) 0.1 (–1
Enzyme activities (mmol mmin–1·mg1 dry weight)
Creatine kinase T0 1118 (383) 1309 (309)
T24 1035 (470) 1483 (302) –7.2 (–2
Citrate synthase T0 32.2 (9.0) 37.0 (15.3)
T24 31.0 (7.1) 51.3 (14.1) 3.8 (–2
Lactate dehydrogenase T0 223.2 (58.6) 253.4 (78.4)
T24 247.8 (87.5) 231.3 (66.8) 12.9 (–1
CI= conﬁdence interval, CG= control group, SD= standard deviation, TG= training group.
∗
TG as reference for mean difference in change.
8during the intervention, consistent with observations that
creatine kinase returned to baseline by 24h following high-
intensity cycling.[26] Serum creatine kinase results in the present
study suggest an absence of muscle structure changes indicating
that sarcolemmal integrity was not degraded with training. Thus,
long-term exercise training appears to be a safe therapeutic
method without muscle damage or adverse effects.
As expected, the VO2 peak andMAP increased in both training
groups (Fig. 4A and B). Improvements in the VO2 peak wererandomized controlled trial.
Predicted mean differences (95% CI)
G %
5% CI)
TG %
(95% CI)
Mean difference
in change
∗
% (95% CI) P
- - - -
0.6 to 12.5) 28.4 (12.6 to 44.2) 32.4 (9.1 to 55.8) 0.015
- - - -
3.7 to 5.2) 39.8 (19.7 to 59.8) 44.0 (21.4 to 66.7) 0.002
- - - -
1.1 to 11.2) 33.7 (15.4 to 52.0) 33.6 (11.8 to 55.5) 0.008
- - - -
6.6 to 12.2) 15.2 (4.7 to 25.6) 22.4 (–0.1 to 44.9) 0.067
- - - -
8.7 to 36.4) 46.1 (25.8 to 66.4) 42.3 (3.1 to 81.4) 0.049
- - - -
0.0 to 35.8) –6.3 (–20.1 to 7.3) –19.3 (–46.5 to 7.9) 0.178
Bankolé et al. Medicine (2016) 95:31 www.md-journal.comaccompanied by greater muscle citrate synthase (+46%) and a
near-signiﬁcant increase in creatine kinase (+15%) activity in TG.
Creatine kinase plays a key role in the regulation of aerobic
metabolism[27] and citrate synthase and creatine kinase work
together to meet the ATP requirements of contracting muscles.
These results suggest improved oxidative phosphorylation with
training. Interestingly, VO2 peak andMAP improvements at T12
were greater than in most dystrophy studies and 12-week FSHD
aerobic training interventions.[8,9] Another FSHD randomized
controlled trial reported no aerobic power improvement after 16
weeks of aerobic training.[6] One potential explanation for the
comparatively large increase in aerobic capacity in the present
study is initial patient ﬁtness level; however, training type was
likely crucial. High-intensity interval training induces greater
improvements in aerobic power compared to continuous aerobic
training.[28] In 3 previous FSHD studies,[6,8,9] continuous aerobic
training was used whereas our study combined continuous
aerobic exercise with interval training. It can be hypothesized that
high-intensity aerobic intervals are more effective in FSHD
patients. Moreover, we observed improvements in VO2 peak and
MAP at T6 and further increases to 24 weeks. MAP increases
after T12 underscore the potential for long-term continuous
aerobic power improvements in FSHD. Thus, our study advances
previous reports of short-term aerobic capacity improvements by
demonstrating aerobic power can be improved beyond 3 months
with combined aerobic and interval training. This has important
practical consequences in designing training programs for FSHD
patients.
Unlike previous FSHD studies,[10,11] combined training
improved maximal quadriceps strength (+14% at T24).
Although some neuromuscular disease studies have shown
strength gains after resistance training, it was unclear whether
neural and/or muscle adaptation (e.g., hypertrophy) mechanisms
underpinned this improvement. High maximal voluntary
activation was observed in both TG and CG at baseline
(∼95%), conﬁrming recent ﬁndings.[12] It was thus unsurprising
that training effects were not observed, suggesting strength gains
were due to structural changes. This was conﬁrmed by muscle
biopsy analysis showing a 34% increase in muscle ﬁber cross-
sectional area at T24. Muscle hypertrophy has been reported to
play a major role in strength enhancement.[29]
Recently, lower quadriceps endurance was reported in FSHD
patients compared to healthy controls.[12] Signiﬁcant improve-
ments in both TG andCTGwere found for muscle endurance and
motor function. As absolute QIF-test target torques were
maintained throughout the 24-week intervention, muscle endur-
ance improvement might be explained by concomitant improve-
ments in aerobic capacity and quadriceps muscle strength. This is
supported by the signiﬁcant positive correlations between muscle
endurance and both MAP and MVC. A positive relationship
between quadriceps endurance and strength in FSHDpatients has
previously been demonstrated with both parameters positively
correlated with functional parameters.[30] Interestingly, another
study reported mitochondrial disruption and oxidative stress are
important causes of muscle weakness and functional muscle
impairment in FSHD.[30] Thus, any intervention limiting
mitochondrial impairment might be useful for maintaining
muscle function. In the present study, increased VO2 peak
suggests possible activation of mitochondrial biogenesis since
citrate synthase increased with training.
Beneﬁcial changes were also observed for motor function (6-
minute walking test) in both TG andCTG and these changes were9positively correlated with changes in VO2 peak, MVC, and
muscle endurance, suggesting increases in both VO2peak and
strength contribute to improved motor function. Subjective
fatigue is a critical symptom for FSHD patients as it is directly
associated with lower functional capacity and quality of life.[31]
In agreement with another recent randomized controlled trial,[6]
the present study observed decreased subjective fatigue with
training that was correlated with increases in VO2 peak, MAP,
MVC, muscle endurance, and 6-minute walking test distance and
improvements in mental health (Short Form Health Survey).
Meanwhile, quality of life scores (Short Form Health Survey)
were unchanged, indicating that despite the progressive and
incurable nature of FSHD and the load of the study, quality of life
during the 24-week training intervention was maintained. This
suggests the beneﬁcial effects of a long-term training program on
experienced fatigue impact motor function and quality of life in
FSHD patients.
The main limit of this trial is patient number. However,
analysis of the primary endpoint (VO2 peak) from 16 patients
showed larger than expected improvements in TG compared to
CG, suggesting that the results are reliable and provide valid
conclusions while encouraging further study.
This study demonstrates clinically relevant beneﬁts of a long-
term training program combining (low-intensity with high-
intensity intervals) aerobic and strength training in FSHD
patients. These beneﬁts occurred without inducing muscle
damage or adverse effects and in spite of the progressive nature
of FSHD. Clinicians are thus encouraged to promote an active
lifestyle based on regular home-based exercise compatible with
patients’ daily professional and social activities as a therapeutic
approach. Based on the time-course of adaptations, long-term
exercise programs should be prescribed in order to optimize the
training effects.
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